$アクチニウム・ファーマシューティカルズ(ATNM.US)$ NEWS Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
$アクチニウム・ファーマシューティカルズ(ATNM.US)$Actinium Pharmaceuticals Granted U.S. Patent #11844799: Method for Treating Cancer Using a BCL-2 Inhibitor in Conjunction With an Alpha-emitting Radioimmunotherapeutic
$アクチニウム・ファーマシューティカルズ(ATNM.US)$Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition PR Newswire· 1 min ago
$アクチニウム・ファーマシューティカルズ(ATNM.US)$Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225) 3 MINUTES AGO, 6:00 AM EST VIA PR NEWSWIRESHARE LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225.
$アクチニウム・ファーマシューティカルズ(ATNM.US)$Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
アクチニウム・ファーマシューティカルズに関するコメント
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Update
Update
PR Newswire· 1 min ago
NO FINANCIAL DETAILS GIVEN YET?
3 MINUTES AGO, 6:00 AM EST
VIA PR NEWSWIRESHARE
LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225.
Update!
Possible more dips ?🤓🤓🤓 still waiting
Looks like current strong support 11.38
Good entry?
This news is so nice long term hold potential
11/1 watchlist
$アーチ・キャピタル・グループ(ACGL.US)$$Aeglea BioTherapeutics(AGLE.US)$$アクチニウム・ファーマシューティカルズ(ATNM.US)$$エイビス・バジェット・グループ(CAR.US)$$カルディオ・ダイアグノスティックス・ホールディング(CDIO.US)$$1847 Holdings(EFSH.US)$ $エッツィー(ETSY.US)$$GETゲッティ・イメージズ・ホールディングス(GETY.US)$$NXPセミコンダクターズ(NXPI.US)$$ティルレイ・ブランズ(TLRY.US)$$バロニス・システムズ(VRNS.US)$
まだコメントはありません